Biotech News
Related news
ZURAZura Bio2026-08-21 23:57 EST
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ZURAZura Bio2026-06-29 11:30 EST
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
AVTXAvalo Therapeutics2026-07-22 11:00 EST
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
AVTXAvalo Therapeutics2026-07-07 11:00 EST
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
EQEquillium, Inc.2026-05-28 20:05 EST
Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
KYMRKymera2026-05-27 11:00 EST
Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
XGNExagen2026-07-28 13:00 EST
Exagen Inc. to Participate in Upcoming Investor Conference
SABSSAB Biotherapeutics2026-05-29 12:00 EST
SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
GRIGRI Bio2026-08-24 14:05 EST
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026
MLTXMoonLake Immunotherapeutics2026-08-10 11:00 EST
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
Zura Bio
Autoimmune and Inflammatory Diseases Zura Bio develops biologics for serious autoimmune and inflammatory diseases, emphasizing combinations of validated immune pathways in single molecules. Tibulizumab Tibulizumab is a bispecific antibody designed to neutralize both IL-17 and BAFF. The dual mechanism targets inflammatory and B-cell...
Recent company news
ZURAZura Bio2026-08-21 23:57 EST
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ZURAZura Bio2026-08-11 11:30 EST
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
ZURAZura Bio2026-06-29 11:30 EST
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
ZURAZura Bio2026-05-14 11:30 EST
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ZURAZura Bio2026-05-13 11:30 EST
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
Stock data
- Close
- 5.85 USD
- Market cap
- 389.01M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States